Company Encyclopedia
View More
name
Mereo Biopharma
MREO.US
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency.
1.946 T
MREO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking237/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-69.79%E
    • Profit Margin-8314.60%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-50.00%E
    • Net Profit YoY8.26%C
    • Total Assets YoY-39.60%E
    • Net Assets YoY-35.76%E
  • Cash ScoreD
    • Cash Flow Margin-1.20%D
    • OCF YoY-50.00%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio13.07%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading

    European equities traded in the US as American Depositary Receipts rose 0.58% on the S&P Europe Select ADR Index. Notable gainers included Sequans Communications and Materialise, while Unilever and Novo Nordisk led the decliners. From the UK and Ireland, GSK and Vodafone Group were among the top gainers, whereas Silence Therapeutics and Mereo BioPharma Group were the main decliners.

    fidelity·
    US
    MREO
    +4.08%
    US
    SLN
    +12.64%
    US
    NVO
    +0.88%
    fidelity·
    US
    MREO
    +4.08%
    US
    SLN
    +12.64%
    US
    NVO
    +0.88%

    European Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading

    European equities traded in the US as American depositary receipts were slightly lower on Monday, down 0.1% to 1,610.86 on the S&P Europe Select ADR Index. Gainers included Cellectis, Ascendis Pharma, DBV Technologies, and Genfit. Decliners included SAP, Banco Santander, Anheuser-Busch InBev, and Philips. From the UK and Ireland, WPP and Mereo BioPharma Group led gainers, while Trinity Biotech and Biodexa Pharmaceuticals led decliners. MT Newswires does not provide investment advice.

    marketscreener·
    US
    BDRX
    +3.67%
    US
    MREO
    +4.08%
    US
    ASND
    +4.03%
    marketscreener·
    US
    BDRX
    +3.67%
    US
    MREO
    +4.08%
    US
    ASND
    +4.03%

    Mereo BioPharma Group (NASDAQ:MREO) Releases Quarterly Earnings Results

    Mereo BioPharma Group (NASDAQ:MREO) reported quarterly earnings of ($0.01) EPS. The stock traded down $0.03 to $1.77, with a market cap of $281.43 million. Institutional investors hold 62.83% of shares. Analysts have mixed ratings, with a consensus target price of $7.40. Weiss Ratings maintains a "sell" rating, while JPMorgan raised its target to $8.00. Mereo develops therapeutics for oncology and rare diseases, with its lead product in Phase 1b trials.

    Market Beat·
    US
    MREO
    +4.08%
    Market Beat·
    US
    MREO
    +4.08%

    Positive Outlook for Mereo Biopharma: Buy Rating on Promising Setrusumab Developments and Strong Financial Position

    Cory Jubinville, PhD from LifeSci Capital, has maintained a Buy rating on Mereo Biopharma Group Plc, setting a price target of $9.00. This positive outlook is based on the promising developments of setrusumab, which is nearing the final analysis of its Phase 3 Orbit study for treating osteogenesis imperfecta. The study's lenient statistical threshold and extended treatment period are expected to enhance efficacy. Mereo's strong financial position, with cash reserves projected to last until 2027, further supports this outlook. Needham also issued a Buy rating with a $5.00 price target.

    Tip Ranks·
    US
    MREO
    +4.08%
    Tip Ranks·
    US
    MREO
    +4.08%

    Positive Outlook for Mereo Biopharma Group Plc Driven by Strong Clinical Progress and Strategic Initiatives

    Analyst Gil Blum from Needham maintains a Buy rating on Mereo Biopharma Group Plc with a price target of $5.00, citing strong clinical progress in Phase III studies and strategic initiatives. The studies are expected to yield positive results by the end of 2025, and the company is seeking a partner for its drug alvelestat. Mereo has $48.7 million in cash, supporting operations until 2027. Blum has a 39.76% success rate on stock recommendations.

    Tip Ranks·
    US
    MREO
    +4.08%
    Tip Ranks·
    US
    MREO
    +4.08%
    © 2025 Longbridge｜Disclaimer